- Home
- PGEN vs CPS Comparison
PGEN vs CPS Comparison
Compare PGEN & CPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PGEN | CPS |
|---|---|---|
| Founded | 1998 | 1960 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 544.9M |
| IPO Year | 2013 | 2005 |
Fundamental Metrics
Financial Performance| Metric | PGEN | CPS |
|---|---|---|
| Price | $4.24 | $28.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $8.33 | ★ $51.88 |
| AVG Volume (30 Days) | ★ 3.0M | 168.1K |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 94.87 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | $4.42 |
| Revenue Next Year | $81.04 | $6.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $20.10 |
| 52 Week High | $5.47 | $47.98 |
Technical Indicators
Market Signals| Indicator | PGEN | CPS |
|---|---|---|
| Relative Strength Index (RSI) | 52.86 | 45.25 |
| Support Level | $3.97 | $24.56 |
| Resistance Level | $4.40 | $32.14 |
| Average True Range (ATR) | 0.25 | 1.85 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 32.61 | 26.67 |
Price Performance
Historical ComparisonAbout PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
About CPS Cooper-Standard Holdings Inc.
Cooper-Standard Holdings Inc is engaged in the manufacture of sealing and fluid handling systems (consisting of fuel and brake delivery systems and fluid transfer systems). Its products are designed for passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers (OEMs) and replacement markets. It has two reportable segments: Sealing Systems and Fluid Handling Systems. The group's geographic regions are North America, Europe, Asia Pacific, and South America.